Classification
Compound class	Synthetic organic
Approved drug?	Yes (source: FDA (2010))
Is prodrug?	Yes
Active form	FTY720-phosphate

IUPAC Name

2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol

International Nonproprietary Names
INN number	INN
8341	fingolimod

Synonyms

FTY-720

FTY720

Gilenya®

Database Links
BindingDB Ligand	50158336
CAS Registry No.	162359-55-9 (source: Scifinder)
ChEBI	CHEBI:63115
ChEMBL Ligand	CHEMBL314854
DrugBank Ligand	DB08868
PubChem CID	107970
Search Google for chemical match using the InChIKey	KKGQTZUTZRNORY-UHFFFAOYSA-N
Search Google for chemicals with the same backbone	KKGQTZUTZRNORY
Search PubMed clinical trials	fingolimod
Search PubMed titles	fingolimod
Search PubMed titles/abstracts	fingolimod
Wikipedia	Fingolimod

Comments

Fingolimod was the first approved oral therapy for multiple sclerosis. Fingolimod FTY720) is the prodrug of a SIP receptor agonist [4]. When fingolimod binds to SIP1 the complex is internalised and then degraded, so the drug acts as an indirect functional antagonist by preventing intracellular signalling. It acts as a lymphocyte migration inhibitor, promoting lymphocyte retention in lymphoid tissues, whilst preserving lymphocyte function [7]. Clinical efficacy results from modulation of subtype 1 S1P (S1P1) receptors. Adverse effects are thought to be caused by fingolimod's off-target effects on othe SIP receptor subtypes. Selective SIP1 receptor agonists are being developed and investigated for immunomodulatory/immunosuppresant potential.